Richard G. Stock, MD, Author at Grand Rounds in Urology

Richard G. Stock, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Richard G. Stock, MD, is a Professor of Radiation Oncology and Director of Genitourinary Radiation Oncology at the Icahn School of Medicine at Mount Sinai in New York City. He has dedicated his career to delivering the highest quality care to patients using the most advanced technology available, including intensity modulated radiation therapy (IMRT), Novalis Shaped Beam Radiosurgery, real-time ultrasound guided prostate seed implants, and MammoSite, all of which allow him to meticulously target tumors while achieving maximal sparing of normal tissues.

Dr. Stock has served on the board of American College of Radiology Testing and the American Brachytherapy Society, where he is member at large, and as guest editor of a special Brachytherapy issue of Techniques in Urology. He has lectured and presented at dozens of meetings and symposiums across the country and internationally, including in New York, San Francisco, Chicago, Philadelphia, Boston, Spain, Holland, France, and Japan.

Dr. Stock completed his internship at Beth Israel Medical Center and his specialty training at Memorial Sloan-Kettering Cancer Center. He is listed in America's Top Doctors.

Talks by Richard G. Stock, MD

Hydrogel Rectal Spacer: Radiopaque vs. Non-radiopaque

Posted by Richard G. Stock, MD | Feb 2025

Richard G. Stock, MD, explores the role of rectal spacers in reducing gastrointestinal toxicity during prostate cancer radiotherapy.

Adaptive Radiotherapy

Posted by Richard G. Stock, MD | Feb 2025

In this 23-minute presentation, Richard D. Stock, MD, explores integrating artificial intelligence in radiation oncology, focusing on adaptive radiation therapy (ART). Three categories of ART—offline, online, and real-time—are detailed, explaining their respective timelines, imaging technologies, and resource requirements. The discussion critically evaluates ART in prostate cancer, where anatomical shifts due to bladder or rectal changes can influence treatment accuracy.

Examples of imaging technologies like MRI and PET scans are discussed for their contributions to ART’s precision and potential to adapt treatment based on tumor shrinkage or biological response. Comparative studies from the Netherlands and other institutions demonstrate ART’s ability to refine target margins, decrease normal tissue exposure, and predict patient outcomes more accurately.

As ART shows promise in improving treatment precision, Dr. Stock emphasizes its potential for advancing radiation oncology, driven by technological innovation and ongoing research.

Panel Discussion: Didactic Session 4: Advances in Radiotherapy

Posted by Steven J. Frank, MD, FACR, FABS, FASTRO, Richard G. Stock, MD, Nelson N. Stone, MD and Juanita M. Crook, MD, FRCPC | Aug 2024

Steven J. Frank, MD, FACR, FABS, FASTRO; Richard G. Stock, MD; Nelson N. Stone, MD; Juanita M. Crook, MD, FRCPC

Panel Discussion: Didactic Session 2: Radioprotection

Posted by Leonard S. Marks, MD, Richard G. Stock, MD and Peter F. Orio III, DO, MS | Aug 2024

Peter F. Orio III, DO, MS; Leonard S. Marks, MD; Richard G. Stock, MD

Adjuvant-Salvage Radiotherapy Following Prostatectomy

Posted by Richard G. Stock, MD | Oct 2023

Richard G. Stock, MD analyzes adjuvant and salvage radiotherapy following prostatectomy in prostate cancer patients with high-risk features or biochemical recurrence post-surgery. Adjuvant radiotherapy is administered shortly after prostatectomy in patients with adverse pathological features, such as positive surgical margins or seminal vesicle invasion, aiming to eradicate microscopic residual disease. Salvage radiotherapy is employed in response to a rising prostate-specific antigen (PSA) level indicating biochemical recurrence after an initial period of undetectable PSA post-surgery.
Dr. Stock reviews pivotal clinical trials and studies, including the SWOG 8794, EORTC 22911, and ARO 96-02 trials, which have demonstrated the efficacy of adjuvant radiotherapy in improving biochemical progression-free survival and overall survival in patients with high-risk features. He highlights the long-term benefits of early intervention with radiotherapy, emphasizing its potential to prevent metastatic progression.